Acuitas Therapeutics

Acuitas Therapeutics is a biotechnology company that specializes in the development of Lipid Nanoparticle (LNP) delivery systems for molecular therapeutics. The company is based in Vancouver, British Columbia, Canada and was founded in 2009.

History[edit | edit source]

Acuitas Therapeutics was founded by Dr. Thomas Madden, a recognized expert in the field of lipid nanoparticle delivery systems. The company was established with the aim of developing and commercializing a new generation of lipid nanoparticle delivery systems for molecular therapeutics.

Lipid Nanoparticle Technology[edit | edit source]

The company's primary focus is on the development of lipid nanoparticle (LNP) delivery systems. These systems are designed to deliver a wide range of molecular therapeutics, including siRNA, mRNA, DNA, proteins and vaccines. The LNP technology encapsulates the therapeutic molecules in tiny lipid particles, which can then be delivered to specific cells in the body.

Role in COVID-19 Vaccine Development[edit | edit source]

Acuitas Therapeutics played a crucial role in the development of the COVID-19 vaccine by BioNTech and Pfizer. The company provided the lipid nanoparticle delivery system that is used in the vaccine to deliver the mRNA into cells. This was a significant contribution to the rapid development and deployment of the vaccine.

Partnerships and Collaborations[edit | edit source]

Acuitas Therapeutics has established several partnerships and collaborations with other biotechnology and pharmaceutical companies. These partnerships have been instrumental in advancing the development and commercialization of LNP delivery systems.